African leaders endorse AIM2030 push to boost local manufacturing at Nairobi summit

Medicines are the point here — not just factories. African leaders used the Africa Forward Summit in Nairobi on May 12 to turn a familiar complaint into a more concrete plan: make more of the continent’s drugs, vaccines, diagnostics, and medical equipment closer to home. The vehicle is AIM2030, a new push tied to governments, the African Union system, the World Bank Group, and health institutions trying to move from speeches to actual production lines. The stakes are simple. If Africa still depends heavily on imports when the next shock hits, it risks getting pushed to the back of the queue again. ### What actually happened in Nairobi? Kenyan President William Ruto used a high-level AIM2030 meeting alongside the Africa Forward Summit to call for faster investment in pharmaceutical manufacturing and what he framed as African “health sovereignty.” The wider summit, co-hosted by Kenya and France on May 11–12, brought heads of state, business leaders, and investors to Nairobi, with health listed as one of the core themes. (eastleighvoice.co.ke) ### What is AIM2030? Basically, AIM2030 — the Africa Initiative for Medical Access and Manufacturing — is a partnership platform meant to do three things at once: expand access to essential medicines, build regional manufacturing capacity, and pull in private capital. It is set up around infrastructure and skills, policy and regulatory reform, and private-sector investment. It launched at the 2026 Africa Forward Summit and is focused first on nine countries: Egypt, Ethiopia, Ghana, Kenya, Morocco, Nigeria, Rwanda, Senegal, and South Africa. (kbc.co.ke) ### Why are leaders pushing this now? Because the numbers are still bad. Ruto said Africa carries nearly 25% of the global disease burden, yet produces less than 6% of its medical supplies, roughly one-third of its pharmaceutical needs, and just 1% of the vaccines it uses. That mismatch is the whole argument for local manufacturing — the continent faces a heavy health load but still buys too much of the response from elsewhere. (ebs.publicnow.com) ### Why does “local manufacturing” matter so much? COVID made the problem painfully visible. When supply chains tightened and rich countries locked in access, African countries were left exposed to delays, export restrictions, and price spikes. The case for local production is not just patriotic branding. It is about resilience — shorter supply chains, more predictable access, and less dependence on outside political decisions in a crisis. (eastleighvoice.co.ke) ### What is the hard part? The catch is that factories alone do not solve this. Ruto and the summit’s health concept note both point to the same bottlenecks: fragmented regulation, weak market integration, infrastructure gaps, skills shortages, and uncertain demand. A drug plant is only bankable if manufacturers can count on approvals, pooled procurement, and buyers across borders. That is why the push keeps pairing production with regulatory harmonization, technology transfer, and digital systems. (eastleighvoice.co.ke) ### Where does Africa CDC fit in? Africa CDC has been pushing this agenda already. In a February 14 declaration adopted on the margins of the AU summit, African leaders backed local manufacturing as a continental priority, reaffirmed a goal of meeting at least 60% of Africa’s health-product needs through local manufacturing by 2040, and supported an extraordinary Nairobi summit on health-products manufacturing in Q2 2026. So Nairobi is not a random side event — it is part of a longer political build. (eastleighvoice.co.ke) ### Is this only about medicines? No — it is broader than pills and vaccine vials. The summit health agenda covers diagnostics, medical technologies, resilient health systems, and stronger surveillance and regulatory capacity. But medicines are the easiest way to see the bigger strategy. If countries can build reliable regional markets for essential health products, they also build industrial capability, skilled jobs, and more bargaining power in future emergencies. (africacdc.org) ### So what should we watch next? Watch for financing and procurement, not just speeches. Africa’s pharmaceutical market was about $30 billion in 2024 and is projected to exceed $50 billion by 2030, which gives the initiative a real commercial story. But the real test is whether governments create predictable demand through the African Continental Free Trade Area, the African Medicines Agency, and pooled purchasing tools that let manufacturers scale beyond one national market. (africaforwardsummit.go.ke) The bottom line is that Nairobi moved this debate one step closer to execution. Africa’s leaders are no longer just saying the continent should make more of its own health products. They are trying to line up the financing, rules, and regional market needed to make that believable. (kbc.co.ke) (eastleighvoice.co.ke)